# DESCRIPTION

## FIELD OF INVENTION

- define antigen-binding proteins
- describe heterodimers of heavy chains

## BACKGROUND OF THE INVENTION

- describe limitations of monoclonal antibodies
- motivate need for bispecific antibody format

## SUMMARY OF THE INVENTION

- introduce bispecific antigen-binding protein
- describe heterodimer formation
- detail CH1 region modification
- specify S40T and T47S mutations
- describe CH1 region selection
- specify human IgG1, IgG2, IgG3, IgG4
- describe CH2 and CH3 domain selection
- specify human lambda and kappa light chains
- describe CDRs
- specify human heavy chain
- describe first and second antigen-binding regions
- specify human framework region
- describe somatic mutation
- describe phage library screening
- describe immunization and antibody variable region identification
- describe human immunoglobulin variable region genes
- describe hybridoma or quadroma screening
- describe bispecific antibody
- specify fully human bispecific antibody
- describe affinity for each epitope
- describe non-immunogenic or substantially non-immunogenic antigen-binding protein
- specify lack of non-native human T-cell epitope
- describe modification of CH1 region
- specify non-immunogenic or substantially non-immunogenic heavy chain
- describe amino acid sequence without non-native T-cell epitope
- describe proteolysis and immunogenicity
- describe isolated multispecific antibodies
- specify first and second polypeptides
- describe first and second epitopes
- specify modification of CH1 region
- describe heterodimeric bispecific antigen-binding proteins
- specify human IgG heavy chains
- describe immunoglobulin light chain
- specify human immunoglobulin light chain
- describe modification in second CH1 domain
- specify S40T and T47S mutations
- describe non-immunogenic or substantially non-immunogenic CH1 domain

## DETAILED DESCRIPTION

- introduce bispecific antibody formats
- motivate multiple antigen targeting
- describe advantages of bispecific antibodies
- summarize limitations of monovalent antibody therapeutics
- describe bispecific antibody formats
- introduce single chain variable fragment (scFv) modules
- describe Bispecific T cell Engager (BiTE) molecules
- summarize disadvantages of BITE format
- introduce hybrid of mouse and rat monoclonal antibody
- describe modification of conventional Protein A affinity chromatography
- summarize disadvantages of mouse/rat hybrid
- introduce other formats relying on modification of Fc region
- describe “knobs-into-holes” strategy
- summarize disadvantages of “knobs-into-holes” strategy
- introduce approach to generate bispecific antibodies
- describe CH1 domain modifications
- summarize benefits of the invention

### EXAMPLES

- introduce Example 1
- describe binding experiments with CaptureSelect IgG-CH1 affinity reagent
- introduce Example 2
- describe sequence alignment of human, hamster, mouse, and rat IgGs
- identify sequence determinants responsible for IgG binding
- introduce Example 3
- describe modification of human CH1 domain
- describe protein A and CaptureSelect IgG-CH1 purification
- introduce Example 4
- describe generation and purification of anti-IL17 x anti-CD3 bispecific antibody
- describe co-expression experiments
- describe purification of bispecific antibody using asymmetric purification
- describe ELISA experiments to determine antibody binding

## OTHER EMBODIMENTS

- describe scope of the invention

